Use of antiviral medications against equine herpes virus associated disorders

Equine Veterinary Education

Volumn 22, Issue 5, 2010, Pages 244-252

  Wong, D M ^a   Maxwell, L K ^a   Wilkins, P A ^b  

^a OKLAHOMA STATE UNIVERSITY   (United States)

^b UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

Acyclovir; Foal; Horse; Myeloencephalopathy; Pulmonary; Valacyclovir

Indexed keywords

EQUID HERPESVIRUS 1; EQUIDAE; HERPESVIRIDAE;

EID: 77952944657     PISSN: 09577734     EISSN: 20423292     Source Type: Journal    
DOI: 10.1111/j.2042-3292.2010.00048.x     Document Type: Article

References (40)

1. Anzivino E, Fioriti D, Mischitelli M, Bellizzi A, Barucca V, Chiarini F, Pietropaolo V. Herpes simplex virus infection in pregnancy and in neonate: status of art of epidemiology, diagnosis, therapy and prevention. Virol. J. 2009, 6:40.
2. Asahi T, Tsutsui M, Wakasugi M, Tange D, Takahashi C, Tokui K, Okazawa S, Okeuera H. Valacyclovir neurotoxicity: clinical experience and review of the literature. Eur. J. Neurol. 2009, 16:457-460.
3. Balfour HH, Hokanson KM, Schacherer RM, Fietzer CM, Schmeling DO, Holman CJ, Vezina HE, Brundage RC. A virologic pilot study of valacyclovir in infectious mononucleosis. J. clin. Virol. 2007, 39:16-21.
4. Bentz BG, Maxwell LK, Erkert RS, Royer CM, Davis MS, MacAllister CG, Clarke CR. Pharmacokinetics of acyclovir after single intravenous and oral administration to adult horses. J. vet. intern. Med. 2006, 20:589-594.
5. Brigden D, Whiteman P. The mechanism of action, pharmacokinetics and toxicity of acyclovir - a review. J. Infect 1983, 6:3-9. .
6. Brown ZA, Selke S, Zeh J, Kopelman J, Maslow A, Ashley RL, Watts DH, Berry S, Herd M, Corey L. The acquisition of herpes simplex virus during pregnancy. N. Engl. J. Med. 1997, 337:509-515.
7. Bryans JT, Allen GP. Application of a chemically inactivated, adjuvanted vaccine to control abortigenic infection of mares by equine herpesvirus I. Dev. Biol. Stand. 1982, 52:493-498.
8. Burki F, Rossmanith W, Nowotny N, Pallan C, Mostl K, Lussy H. Viraemia and abortions are not prevented by two commercial equine herpesvirus-1 vaccines after experimental challenge of horses. Vet. Q. 1990, 12:80-86.
9. Burrows R, Goodridge D, Denyer MS. Trials of an inactivated equid herpesvirus 1 vaccine: challenge with a subtype 1 virus. Vet. Rec. 1984, 114:369-374.
10. De Clercq E, Holy A, Rosenberg I, Sakuma T, Balzarini J, Maudgal P. A novel selective broad-spectrum anti-DNA virus agent. Nature 1986, 323:464-467.
11. De la Fuente R, Awan AR, Field HJ. The acyclic nucleoside analogue penciclovir is a potent inhibitor of equine herpesvirus type 1 (EHV-1) in tissue culture and in a murine model. Antiviral Res. 1992, 18:77-89.
12. Del Piero F, Wilkins PA. Pulmonary vasculotropic EHV-1 infection in equids. Vet. Pathol. 2001, 38:474.
13. Donaldson MT, Sweeney CR. Herpesvirus myeloencephalopathy in horses: 11 cases (1982-96). J. Am. vet. med. Ass. 1998, 213:671-675.
14. Friday PA, Scarratt WK, Elvinger F, Timoney PJ, Bonda A. Ataxia and paresis with equine herpesvirus type 1 infection in a herd of riding school horses. J. vet. intern. Med. 2000, 14:197-201.
15. Garre B, Gryspeerdt A, Croubels S, De Backer P, Nauwynck H. Evaluation of orally administered valacyclovir in experimentally EHV1-infected ponies. Vet. Microbiol. 2009, 135:214-221.
16. Garre B, Baert K, Nauwynck H, Deprez P, Debacker P, Croublels S. Multiple oral dosing of valacyclovir in horses and ponies. J. vet. Pharmacol. Ther. 2008, 32:207-212.
17. Garre B, Shebany K, Gryspeerdt A, Baert K, van der Meulen K, Nauwynck H, Deprez P, De Backer P, Croubels S. Pharmacokinetics of acyclovir after intravenous infusion of acyclovir and after oral administration of acyclovir and its prodrug valacyclovir in healthy adult horses. Antimicrob. Agents Chemother. 2007a, 51:4308-4314.
18. Garre B, van der Meulen K, Nugent J, Neyts J, Croubels S, De Backer P, Nauwynck H. In vitro susceptibility of six isolates of equine herpesvirus 1 to acyclovir, ganciclovir, cidofovir, adefovir, PMEDAP and foscarnet. Vet. Microbiol. 2007b, 122:43-51.
19. Hayden F. Antimicrobial agents (continued) Antiviral agents (nonretroviral). Goodman & Gillman's the Pharmacological Basis of Therapeutics 2001, 1313-1348. Hardman JLimbird L. In, 10th, edn., Eds, McGraw-Hill, New York, pp
20. Henninger RW, Reed SM, Saville WJ, Allen GP, Hass GF, Kohn CW, Sofaly C. Outbreak of neurologic disease caused by equine herpesvirus-1 at a university equestrian center. J. vet. intern. Med. 2007, 21:157-165.
21. Long MC, Bidanset DJ, Williams SL, Kushner NL, Kern ER. Determination of antiviral efficacy against lymphotropic herpesviruses utilizing flow cytometry. Antiviral Res. 2003, 58:149-157.
22. Lunn DP, Davis-Poynter N, Flaminio MJ, Horohov DW, Osterrieder K, Pusterla N, Townsend H. Equine herpesvirus-1 consensus statement. J. vet. intern. Med. 2009, 23:450-461.
23. Maxwell LK, Bentz BG, Bourne DW, Erkert RS. Pharmacokinetics of valacyclovir in the adult horse. J. vet. Pharmacol. Ther. 2008, 31:312-320.
24. Maxwell LK, Bentz BG, Gilliam LL, Ritchey JW, Eberle RW, Holbrook TC, Mcfarlane D, Rezabek GB, MacAllister CG, Goad CL, Allen GP. Efficacy of valacyclovir against disease following EHV-1 challenge: Proc. Am. Coll. vet. intern. Med. 2009, 176.
25. Murray MJ, Piero F, Jeffrey SC, Davis MS, Furr MO, Dubovi EJ, Mayo JA. Neonatal equine herpesvirus type 1 infection on a thoroughbred breeding farm. J. vet. intern. Med. 1998, 12:36-41.
26. Neyts J, De Clercq E. In vitro and in vivo inhibition of murine gamma herpesvirus 68 replication by selected antiviral agents. Antimicob. Agents Chemother. 1998, 42:170-172.
27. Ormrod D, Goa K. Valaciclovir: a review of its use in the management of herpes zoster. Drugs 2000, 59:1317-1340.
28. Schmidt S, Barbour A, Sahre M, Rand KH, Derendorf H. PK/PD: new insights for antibacterial and antiviral applications. Curr. Opin. Pharmacol. 2008, 8:549-556.
29. Schreiber R, Wolpin J, Koren G. Determinants of acyclovir-induced nephrotoxicity in children. Paediatr. Drugs 2008, 10:135-139.
30. Smith KO, Galloway KS, Hodges SL, Ogilvie KK, Radatus BK, Kalter SS, Heberling RL. Sensitivity of equine herpesviruses 1 and 3 in vitro to a new nucleoside analogue, 9-[[2-hydroxy-1-(hydroxymethyl) ethoxy] methyl] guanine. Am. J. vet. Res. 1983, 44:1032-1035.
31. Tod M, Lokiec F, Bidault R, De Bony F, Petitjean O, Aujard Y. Pharmacokinetics of oral acyclovir in neonates and in infants: a population analysis. Antimicrob. Agents Chemother. 2001, 45:150-157.
32. Van Dyke RB, Connor JD, Wyborny C, Hintz M, Keeney RE. Pharmacokinetics of orally administered acyclovir in patients with herpes progenitalis. Am. J. Med. 1982, 73:172-175.
33. Weinberg A, Leary JJ, Sarisky RT, Levin MJ. Factors that affect in vitro measurement of the susceptibility of herpes simplex virus to nucleoside analogues. J. clin. Virol. 2007, 38:139-145.
34. Whitley RJ, Blum MR, Barton N, de Miranda P. Pharmacokinetics of acyclovir in humans following intravenous administration. A model for the development of parenteral antivirals. Am. J. Med. 1982, 73:165-171.
35. Wilkins PA. Acyclovir in the treatment of EHV-1 myeloencephalopathy: Proc. Am. Coll. vet. intern. Med. 2004, 170-172.
36. Wilkins PA, Henninger RW, Reed S. Acyclovir as a treatment for EHV-1 myeloencephalopathy: Proc. Am. Ass. equine Practnrs. 2003, 49:394-396.
37. Wilkins PA, Papich M, Sweeney R. Pharmacokinetics of acyclovir in adult horses. J. vet. emerg. crit. Care. 2005, 15:174-178.
38. Williams KJ, Maes R, Del Piero F, Lim A, Wise A, Bolin DC, Caswell J, Jackson C, Robinson NE, Derksen F, Scott MA, Uhal BD, Li X, Youssef SA, Bolin SR. Equine multinodular pulmonary fibrosis: a newly recognized herpesvirus-associated fibrotic lung disease. Vet. Pathol. 2007, 44:849-862.
39. Wong DM, Scarratt WK. Equine herpes myeloencephalopathy in a 12-year-old American Quarter horse. Vet. Clin. N. Am.: Equine Pract. 2006, 22:177-191.
40. Wong DM, Belgrave RL, Williams KJ, Del Piero F, Alcott CJ, Bolin SR, Marr CM, Nolen-Walston R, Myers RK, Wilkins PA. Multinodular pulmonary fibrosis in five horses. J. Am. vet. med. Ass. 2008, 232:898-905.